治療薬ワクチン市場- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年製品別、技術別、地域別、競合別に区分

治療用ワクチンの世界市場は、2022年には278億1,000万米ドルと評価され、予測期間を通じて堅調な成長を遂げ、2028年には年間平均成長率（CAGR）9.68%を達成し、483億2,000万米ドルに達すると予測されています。

治療用ワクチンは、既存の疾病を予防するのではなく、治療または緩和するために設計された特殊なワクチンです。将来の感染を防ぐために健康な人に投与される従来の予防ワクチンとは対照的に、治療用ワクチンはすでに病気に罹患している人に投与されます。その目的は、免疫系を活性化させ、より効果的に標的を定めて病気と闘うことです。治療用ワクチンに関連する健康上の利点に対する意識の高まりは、世界市場の拡大にプラスの影響を与えると予想されます。

主な市場促進要因：

1.疾病負担の増加が市場成長を牽引

がん、慢性感染症、自己免疫疾患、神経変性疾患など、様々な疾患の負担増が世界の治療用ワクチン市場の主要な促進要因となっています。これらの疾病に罹患する人の増加に伴い、治療用ワクチンのような革新的な治療ソリューションに対する需要が高まっています。これらのワクチンは、根本的な原因に対処するための代替アプローチを提供し、既存の治療法を超える潜在的な利益をもたらします。

2.免疫学の進歩が市場成長の原動力：

免疫学の進歩は、より標的を絞った効果的な治療用ワクチンの開発を可能にし、世界の治療用ワクチン市場を前進させる上で極めて重要な役割を果たしています。免疫系の機能に対する理解が深まることで、ワクチンの設計や最適化が可能になります。この知識は、がん細胞や慢性感染病原体のような疾病原因物質に対する免疫反応を引き起こすことを目的とする治療用ワクチンにとって特に重要です。

3.ヘルスケア支出の増加：

ヘルスケア支出の増加は、世界の治療用ワクチン市場の拡大に大きく寄与しています。ヘルスケア支出の増加は医療研究開発を支援し、治療用ワクチンの進歩につながります。新規ワクチンの上市には強固な臨床試験プログラムが不可欠であり、資金増はこうした試験を促進します。また、十分な資金は研究機関、製薬企業、学術センター間の協力関係を促進し、治療用ワクチン開発のイノベーションを促進します。

主な市場課題

1.科学的複雑性：

特定の疾病を効果的に標的とするワクチンの設計・開発には、科学的な複雑さによる大きな課題があります。免疫システム、疾病特性、ワクチンメカニズムに関連する様々な要因がこの複雑さに寄与しています。疾患特異的なワクチンデザイン、個体間の免疫系のばらつき、適切な抗原の選択などは、ワクチン開発で直面する課題のひとつです。

2.長い開発期間：

長い開発期間は、新しいワクチンの迅速な市場投入を妨げます。この遅延は、患者の救命治療へのアクセスに影響を与え、競合他社が同様の製品をより早く開発することを可能にし、市場機会を逃す可能性があります。進行の早い疾患や治療が重要な疾患は特に影響を受ける。

3.製造上の課題：

製造の複雑さは、治療用ワクチンの製造、品質、スケーラビリティに影響を与えます。一貫した製品品質を確保し、大規模製造における課題を克服することは極めて重要です。製造工程におけるばらつきは、ワクチンの効能や性能に影響を与える可能性があります。特定の治療用ワクチンには特殊な機器や設備が必要な場合があり、これが製造上の課題の一因となっています。

主な市場動向：

1.ナノテクノロジーとドラッグデリバリー：

ナノテクノロジーとドラッグデリバリーの革新は世界の治療用ワクチン市場の主要動向であり、ワクチンの有効性と標的送達を強化するソリューションを提供します。ナノテクノロジーは、安定性、生物学的利用能、免疫反応を改善する新規ワクチン製剤の設計を可能にします。ナノ粒子は、病原体を模倣したり、免疫系をより効果的に活性化するような方法で抗原を提示したりすることができ、より強力で長持ちする免疫応答につながる可能性があります。

2.セグメント別の洞察

自己免疫疾患ワクチンは、このような複雑な病態における免疫反応を調節する可能性があるため、市場を独占しています。しかし、臨床試験における課題、疾患の進行の多様性、既存治療との競合が自己免疫疾患のワクチン開発に影響を与えています。

3.技術的洞察

同種ワクチンは、製造、標準化、安全性が容易であるため、自家ワクチンよりも優位性があります。同種ワクチンは大量生産が可能で、より広く入手できるため、同市場における優位性を牽引しています。

地域別インサイト

1.北米：

北米：がんの流行、研究開発費の増加、健康維持に対する意識の高まりにより、北米市場の成長が予想されます。同地域におけるがんの流行は、治療用がんワクチンの需要を押し上げると思われます。

2.欧州：

欧州は、堅調なバイオ医薬品産業、確立された製薬会社、研究機関が牽引し、治療用ワクチン市場で最も急成長する市場となる見込みです。欧州諸国の臨床試験や規制プロセスにおける経験がワクチン開発を支え、市場の成長に寄与しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の治療用ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（自己免疫疾患ワクチン,神経疾患ワクチン,がんワクチン,感染症ワクチン,その他）
  • 技術別（同種ワクチン,自家ワクチン）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 北米治療ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の治療用ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の治療用ワクチン市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米治療ワクチン市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカ治療ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 臨床試験分析

第12章 臨床試験分析市場力学

• 促進要因と課題

第13章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第14章 世界の治療用ワクチン市場SWOT分析

第15章 競合情勢

• genus Inc.
• Argos Therapeutic Inc.
• Celldex Therapeutic Inc.（Avant Immunotherapeutics, Inc.）
• Dendreon Corp（Sanpower Group Co., Ltd.）
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer, Inc.
• Phio Pharmaceuticals Corp.
• AstraZeneca PLC
• BioNTech SE

第16章 戦略的提言

第17章 調査会社・免責事項

The Global Therapeutics Vaccine Market was valued at USD 27.81 Billion in 2022, and it is projected to experience robust growth throughout the forecast period, achieving a Compound Annual Growth Rate (CAGR) of 9.68% and reached USD 48.32 Billion through 2028. Therapeutics vaccines are a specific type of vaccine designed to treat or mitigate existing diseases rather than solely preventing them. In contrast to conventional preventive vaccines administered to healthy individuals to ward off future infections, therapeutic vaccines are given to those already affected by a disease. The purpose is to activate the immune system to more effectively target and combat the disease. The increasing awareness of the health benefits linked with therapeutic vaccines is expected to positively influence global market expansion.

Therapeutic cancer vaccines are in development to stimulate the immune system to identify and attack cancer cells. These vaccines can complement other cancer treatments like chemotherapy or radiation therapy. The objective is to enhance the body's inherent defense mechanisms to selectively target and eliminate cancer cells, potentially resulting in improved treatment outcomes. Therapeutic vaccines also hold promise in addressing chronic infections such as HIV, hepatitis B, and hepatitis C. These vaccines aim to amplify the immune response against the infectious agent, aiding the body in managing the infection and minimizing its adverse effects. The potential applications of therapeutic vaccines could expand with advancements in medical research and technology. However, their effectiveness and usage rely on rigorous scientific exploration and regulatory approval.

Key Market Drivers:

1. Increasing Disease Burden Drives Market Growth:

The rising burden of various diseases, including cancer, chronic infections, autoimmune disorders, and neurodegenerative conditions, is a major driver for the global therapeutic vaccine market. With a growing number of individuals affected by these diseases, there is a heightened demand for innovative treatment solutions such as therapeutic vaccines. These vaccines offer an alternative approach to addressing underlying causes, offering potential benefits beyond existing treatments.

2. Advances in Immunology Fuel Market Growth:

Progress in immunology plays a pivotal role in propelling the global therapeutic vaccine market forward by enabling the development of more targeted and effective therapeutic vaccines. Enhanced understanding of immune system functions informs the design and optimization of vaccines. This knowledge is especially crucial for therapeutic vaccines, which aim to trigger immune responses against disease-causing agents like cancer cells or chronic infection pathogens.

3. Rising Healthcare Expenditure:

Increased healthcare spending significantly contributes to the expansion of the global therapeutic vaccine market. Higher healthcare expenditure supports medical research and development, leading to advancements in therapeutic vaccines. Robust clinical trial programs are essential for bringing new vaccines to market, and increased funding facilitates these trials. Adequate funding also fosters collaborations among research institutions, pharmaceutical companies, and academic centers, driving innovation in therapeutic vaccine development.

Key Market Challenges:

1. Scientific Complexity:

The intricate nature of designing and developing vaccines that effectively target specific diseases presents a substantial challenge due to scientific complexity. Various factors related to the immune system, disease characteristics, and vaccine mechanisms contribute to this complexity. Disease-specific vaccine design, immune system variability among individuals, and the selection of suitable antigens are among the challenges faced in vaccine development.

2. Long Development Timelines:

Long development timelines hinder the rapid availability of new vaccines in the market. This delay impacts patient access to potentially life-saving treatments and allows competing companies to advance similar products more quickly, potentially leading to missed market opportunities. Diseases with rapid progression or critical treatment windows are particularly affected.

3. Manufacturing Challenges:

Manufacturing complexities affect the production, quality, and scalability of therapeutic vaccines. Ensuring consistent product quality and overcoming challenges in large-scale manufacturing are critical. Variability in manufacturing processes can impact vaccine efficacy and performance. Specialized equipment and facilities may be required for certain therapeutic vaccines, contributing to production challenges.

Key Market Trends:

1. Nanotechnology and Drug Delivery:

Nanotechnology and drug delivery innovations are key trends in the global therapeutic vaccine market, offering solutions to enhance vaccine effectiveness and targeted delivery. Nanotechnology allows for the design of novel vaccine formulations that improve stability, bioavailability, and immune responses. Nanoparticles can mimic pathogens or present antigens in ways that activate the immune system more effectively, potentially leading to stronger and longer-lasting immune responses.

2. Segmental Insights:

Autoimmune disease vaccines dominate the market due to their potential to modulate immune responses in these complex conditions. However, challenges in clinical trials, variable disease progression, and competition from existing treatments impact vaccine development for autoimmune diseases.

3. Technology Insights:

Allogeneic vaccines hold an advantage over autologous vaccines due to easier manufacturing, standardization, and safety. Allogeneic vaccines can be produced in larger quantities and are more widely available, driving their dominance in the market.

Regional Insights:

1. North America:

The North American market is anticipated to grow due to the ongoing cancer epidemic, increasing R&D spending, and growing awareness of health maintenance. The prevalence of cancer in the region will likely drive the demand for therapeutic cancer vaccines.

2. Europe:

Europe is poised to be the fastest-growing market for therapeutic vaccines, driven by its robust biopharmaceutical industry, established pharmaceutical companies, and research institutions. European countries' experience in clinical trials and regulatory processes supports vaccine development, contributing to the growth of the market.

Key Market Players

• Genus Inc.
• Argos Therapeutic Inc.
• Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
• Dendreon Corp (Sanpower Group Co., Ltd.)
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer, Inc.
• Phio Pharmaceuticals Corp.
• AstraZeneca PLC
• BioNTech SE

Report Scope:

In this report, the Global Therapeutics Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutics Vaccine Market, By Product:

• Autoimmune Disease Vaccines
• Neurological Disease Vaccines
• Cancer Vaccines
• Infectious Disease Vaccines
• Other

Therapeutics Vaccine Market, By Technology:

• Allogeneic Vaccine
• Autologous Vaccine

Therapeutics Vaccine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Therapeutics Vaccine Market.

Available Customizations:

• Global Therapeutics Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutics Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Other)
  • 5.2.2. By Technology (Allogeneic Vaccine, Autologous Vaccine)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. North America Therapeutics Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Therapeutics Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
  • 6.3.2. Canada Therapeutics Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
  • 6.3.3. Mexico Therapeutics Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology

7. Europe Therapeutics Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Therapeutics Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
  • 7.3.2. United Kingdom Therapeutics Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
  • 7.3.3. Italy Therapeutics Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
  • 7.3.4. France Therapeutics Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
  • 7.3.5. Spain Therapeutics Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology

8. Asia-Pacific Therapeutics Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Therapeutics Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
  • 8.3.2. India Therapeutics Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
  • 8.3.3. Japan Therapeutics Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
  • 8.3.4. South Korea Therapeutics Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
  • 8.3.5. Australia Therapeutics Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology

9. South America Therapeutics Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Therapeutics Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
  • 9.3.2. Argentina Therapeutics Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
  • 9.3.3. Colombia Therapeutics Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology

10. Middle East and Africa Therapeutics Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Therapeutics Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
  • 10.3.2. Saudi Arabia Therapeutics Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
  • 10.3.3. UAE Therapeutics Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology

11. Clinical Trial Analysis

12. Market Dynamics

• 12.1. Drivers & Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Merger & Acquisition

14. Global Therapeutics Vaccine Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Technology Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. genus Inc.
  • 15.5.2. Argos Therapeutic Inc.
  • 15.5.3. Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
  • 15.5.4. Dendreon Corp (Sanpower Group Co., Ltd.)
  • 15.5.5. GlaxoSmithKline plc
  • 15.5.6. Merck & Co. Inc.
  • 15.5.7. Novartis AG
  • 15.5.8. Pfizer, Inc.
  • 15.5.9. Phio Pharmaceuticals Corp.
  • 15.5.10. AstraZeneca PLC
  • 15.5.11. BioNTech SE

16. Strategic Recommendations

17. About Us & Disclaimer